Scleroderma laboratory findings: Difference between revisions

	Scleroderma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Scleroderma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Scleroderma laboratory findings On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Scleroderma laboratory findings All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Scleroderma laboratory findings
CDC on Scleroderma laboratory findings
Scleroderma laboratory findings in the news
Blogs on Scleroderma laboratory findings
Directions to Hospitals Treating Scleroderma
Risk calculators and risk factors for Scleroderma laboratory findings

Revision as of 01:22, 6 February 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

@@ Line 5: / Line 5: @@
 ==Overview==
 ==Laboratory Findings==
-Diagnosis is by clinical suspicion, presence of autoantibodies (specifically [[anti-centromere antibodies|anti-centromere]] and anti-scl70/[[anti-topoisomerase antibodies]]) and occasionally by biopsy. Of the antibodies, 90% have a detectable [[anti-nuclear antibody]]. Anti-centromere antibody is more common in the limited form (80-90%) than in the systemic form (10%), and anti-scl70 is more common in the diffuse form (30-40%) and in African-American patients (who are more susceptible to the systemic form).<ref name=JimenezDerk>{{cite journal |author=Jimenez SA, Derk CT |title=Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis |journal=Ann. Intern. Med. |volume=140 |issue=1 |pages=37-50 |year=2004 |pmid=14706971 |doi=}}</ref>
 ==References==